Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation
about
Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCRNeurofibromatosis type 1 - a model for nervous system tumour formation?Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumoursNeurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytesRadiation-associated neoplasia: clinical, pathological and genomic correlates.Neurofibromatosis: chronological history and current issues.Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasmsCo-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors.Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumoursTrp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.Zebrafish models of p53 functions.TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.The NF1 gene revisited - from bench to bedside.Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors.Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discoveryPathogenesis of hereditary tumors: beyond the "two-hit" hypothesis.Neurofibromatosis-related tumors: emerging biology and therapies.Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study.A huge neurofibroma of the lower back invading the spinal cavity.Genetics of neurofibromatosis 1-associated peripheral nerve sheath tumors.Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromasTumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform NeurofibromaDiagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.Diagnosis and treatment options for nerve sheath tumors.Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesisThe Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.How does the Schwann cell lineage form tumors in NF1?Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-cateninPreclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.
P2860
Q24795409-DB2B4D5F-668D-416C-8C51-EB6B523665C2Q28265284-215A03C0-C397-4DA3-AB0F-A6262A444BDEQ28306740-841EF048-EEAB-42D3-BDA8-22F8396D46ECQ28506980-C6E03C84-BA66-4D52-B561-24458AA51416Q30240080-3DC5AD3B-C80D-4297-A62C-896CFD47F321Q30449267-979C575B-8A23-4792-AD67-D6CE18EB32F8Q30457681-DA95177B-8A06-45B0-8FA3-9F54127E703FQ33688908-56E6B84D-8CE0-4D4D-ADE1-96D60489DEB1Q33722903-68FC5DEC-45FF-43C2-9E31-B003E585B6F2Q33758070-BB171B33-456C-47B7-8B45-E4CE2B5B6201Q33826589-5F1FA874-296D-4329-B70A-1E61A02BEBDDQ33884193-E6143B75-4264-4822-952B-91A90F6B3CB5Q34014685-DAF08617-B75F-40D7-8E1D-FB2E07C9AAC5Q34105259-C40E0D01-3390-4B4B-9C7B-5117CA4923A4Q34227509-0BC0C764-C020-4D91-ABF2-00CDBA3D8EBEQ34467060-BDBB0B3C-17AB-4949-B861-BEF59E3FE8A1Q34729614-C730D677-905C-43D5-8120-CA8AD4C84FEEQ34979403-FF79A94D-41A5-464D-8449-243142147EBDQ34996618-D1E5DEB9-BB53-4551-BE3F-9ACFF4390C43Q35218073-0A631A45-D7CA-470D-B97A-9AE561CEFF8EQ35558868-66E0C0CC-4BDE-4F7B-AC37-DAC3E212BFAFQ35588092-34E2855F-5E10-462F-964B-14DBB864512FQ35630999-63AE9C92-9973-454E-8A70-BA94FA836125Q35634817-C54FD8CC-37F5-4A65-B3F0-357C4F2314C7Q35686940-B3374ED2-5F65-4723-AAEE-CA12DACC57E4Q35740953-202AC7CF-7BD2-41B0-AD92-1D1D27668BEEQ35837640-01A5BC93-3A91-43CE-BE31-04ED6E35E9F6Q35973936-8895FE18-3CCA-4815-8571-33F6C287CD3EQ36070199-E55DD927-01CB-4872-8995-B87ABCC28E23Q36133106-B5FCB6F5-FD3C-466C-B065-D268FEC0F15DQ36198617-2B3A9D57-4548-4136-85F3-E73681DAA232Q36651930-31CCF4A9-1103-4506-AC2B-0C0EDF3E48C6Q36753692-D5946AE3-936C-4922-8BC8-2FC6BA801939Q37089105-074EC450-74A9-406B-A96B-91641D8ADD6AQ37120518-458B07A4-39D0-4057-A8F7-E6A8301BBCA6Q37395350-510BEA81-2F1F-4D25-978E-F52E88F106FBQ37441728-801B56DE-BBFB-4315-9A23-B02F55115E3AQ37616238-D9D5C2DE-6BB7-4C48-8761-23B68A22D411Q37619722-6533BD44-6B46-4C66-B3AA-55185A314D7BQ37625501-3B31988A-5171-4385-96F4-2043BEDB3C58
P2860
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@ast
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@en
type
label
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@ast
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@en
prefLabel
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@ast
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@en
P2093
P2860
P1476
Malignant transformation of ne ...... d with CDKN2A/p16 inactivation
@en
P2093
A E Rosenberg
A O Stemmer-Rachamimov
G P Nielsen
P2860
P304
P356
10.1016/S0002-9440(10)65507-1
P407
P577
1999-12-01T00:00:00Z